The MCED Inflection Point: What Galleri's FDA Panel Backing Means for Cancer Screening
Dr. Dereck Mush, MD, MBA
Mirxes
Develops microRNA liquid biopsy tests for the early detection of gastric and other cancers.
What they do
Mirxes produces high-sensitivity blood-based microRNA PCR assays for early cancer detection. Healthcare institutions and clinical laboratories deploy its GASTROclear test to detect early-stage stomach cancers before symptoms manifest, improving patient survival rates through early intervention.
The record
- Vertical
- Oncology
- Sub-segment
- Cancer screening and diagnostics
- Product type
- Diagnostics
- Stage
- Series C+
- Headquarters
- Singapore
- Region
- Asia-Pacific
- Founded
- 2014
- Total funding
- $177M raised
Notable investors: Rock Springs Capital, Banyan Tree Investment Group, CR-CP Life Science Fund, Beijing Venture Capital.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
The barbershop health screening model is expanding well beyond blood pressure
Dr. Dereck Mush, MD, MBA
Screening Programs Are Rebuilding Around Reminder Systems That Actually Reach People
Dr. Dereck Mush, MD, MBA
PATHFINDER 2 Results: What the Galleri Multi-Cancer Blood Test Actually Found
Dr. Dereck Mush, MD, MBA